Move to allow purchase of Canadian drugs rejected

October 2011
Modern Healthcare;10/24/2011, Vol. 41 Issue 43, p4
Trade Publication
This article reports on the U.S. Senate's disapproval of an amendment to the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill.


Related Articles

  • Laws fail to slow gray market. Lee, Jaimy // Modern Healthcare;10/3/2011, Vol. 41 Issue 40, p14 

    The article expresses the concern of pharmacists and health providers regarding the short supply of drugs sold by secondary distributors. It says that there were 210 cases of drug shortages reported as of September 26, 2011 and that drugs purchased from the gray market were often priced 20 times...

  • Illegitimate companies threaten patients' receipt of FDA-approved drugs. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;10/1/2013, Vol. 70 Issue 19, p1646 

    The article focuses on the health risks posed by the purchase of unapproved medications in the U.S. During the 2012-13 period, several letters were sent by the Food and Drug Administration (FDA) to clinics and medical practices regarding these medications. According to Allergan Inc. attorney...

  • Helping to shape drug shortage provisions in FDA user fee legislation. Keating, Armand // MLO: Medical Laboratory Observer;Oct2012, Vol. 44 Issue 10, p38 

    The article focuses on the U.S. FDA Safety and Innovation Act of 2012 which reauthorizes the FDA's user fee programs for five years and creating user fee programs for generic and biologic drugs. The law also addresses the problem of drug shortages which have had particularly devastating effects...

  • Duel over discounts: Pharma, providers at odds over 'orphan drugs' Daly, Rich // Modern Healthcare;1/23/2012, Vol. 42 Issue 4, p30 

    The article reports on an effort by U.S. hospitals to push for greater discounts on orphan drugs while the pharmaceutical industry intends to boost their profits from these drugs. Factors contributing to the financial promise of orphan drugs include longer exclusivity, an expedited regulatory,...

  • Patient Safeguards Needed for Biosimilar Development.  // Chicago Citizen - Chatham Southeast Edition;10/22/2014, Vol. 49 Issue 31, p16 

    The article focuses on the efforts of licensing for medications known as "biosimilars," similar to cutting-edge biologic medicines under the provision of the U.S. Patient Protection and Affordable Care Act. It mentions that the U.S. Food and Drug Administration (FDA), accepted the first...

  • Record high drug shortages warrant FDA policy changes, AHA tells House health panel.  // AHA News;7/11/2011, Vol. 47 Issue 14, p1 

    The article reports on the action of the U.S. Food and Drug Administration to avoid drug shortages, such as the implementation of the Prescription Drug User Fee Act and the Preserving Access to Life Saving Medications Act.

  • FDA May Alter Rules on Drug Combos.  // Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p93 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to change rules enabling manufacturers greater leeway in developing drug combinations.

  • FDA Actions.  // CenterWatch Monthly;Nov2015, Vol. 22 Issue 11, p16 

    A chart is presented depicting a sampling of the U.S. Food and Drug Administration (FDA) regulatory actions taken during October 2015.

  • FDA: Most Drugmakers Meet Postmarketing Commitments. Young, Donna // BioWorld Today;11/11/2010, Vol. 21 Issue 219, p1 

    The article reports on an analysis by Booz-Allen-Hamilton (BAH) of 1,551 backlogged postmarketing studies from 1977 to 2007 which showed that most drug and biologic manufacturers required to complete postmarketing studies are meeting their commitments. According to the results, which were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics